(no title)
xitrium | 2 years ago
At least this paper tests both cognitive abilities as well as "amyloid-β pathologies." I'm not at all an expert in this field but gold nanoparticles sounds like something you'd see on a late night infomercial, lol.
xitrium | 2 years ago
At least this paper tests both cognitive abilities as well as "amyloid-β pathologies." I'm not at all an expert in this field but gold nanoparticles sounds like something you'd see on a late night infomercial, lol.
epistasis|2 years ago
The problem is viewing individual papers as the unit of truth in science. The "self-correcting" nature of science will actually reject entire papers, and entire directions of inquiry. Including, maybe, a casual relationship between beta amyloid and AD, but maybe not.
The other key part of science is holding everything in a state of uncertainty. There's some "facts" but mostly just hints and clues. And with Alzheimer's disease in particular we are trying to make progress with completely inadequate vision; we really can't even measure so much of what we want to measure. Feynman said it back in the 1960s, too, physicists have failed to deliver the tools to biologists to really measure what needs to be measured. There have been advancements, and DNA sequencing technology in the past decade has been turned into the most clever sorts of information theoretic microscopy by combining DNA sequences with many other biochemical processes. But we as a species still can not measure a lot of the things we'd like to measure.
xitrium|2 years ago
> Every single disease-modifying trial of Alzheimer’s has failed.
> The huge majority of those have addressed the amyloid hypothesis, of course, from all sorts of angles. Even the truest believers are starting to wonder. Dennis Selkoe’s entire career has been devoted to the subject, and he’s quoted in the Science article as saying that if the trials that are already in progress also fail, then “the A-beta hypothesis is very much under duress”. Yep.
And the original expose is quite interesting if you haven't read it yet https://www.science.org/content/article/potential-fabricatio...
epistasis|2 years ago
Marc Tessier-Lavigne https://stanforddaily.com/2023/02/17/internal-review-found-f...
Berislav Zlokovic https://www.science.org/content/article/misconduct-concerns-...
Hoau-Yan Wang https://www.science.org/content/article/co-developer-cassava...
Sylvain Lesné - the researcher from grandparent comment's article
This list taken from Chris Said on Twitter https://x.com/chris_said/status/1724448550493315436?s=46
brnaftr361|2 years ago
SubiculumCode|2 years ago
instagraham|2 years ago
The plaques are known to be linked to Alzheimer's, the debunking of one paper that messed with its figures does not detract from the whole body of research. The inefficacy of plaque-targeting treatments may not be proof that the plaques are not causal in nature, only that their damage is not reversible/fully understood.
Etheryte|2 years ago
[0] https://news.ycombinator.com/item?id=37572394
mft_|2 years ago
The issue in the Alzheimer's world is the possibility that the very disease mechanism concept underlying the vast majority of research and interventional trials into which countless multiple billions have been poured, is incorrect.
Within that space, this is orders of magnitude more fundamental and serious than a flip aside that lots of trials have problems, so who cares about another?
InSteady|2 years ago
>For more than 150 trials, Carlisle got access to anonymized individual participant data (IPD). By studying the IPD spreadsheets, he judged that 44% of these trials contained at least some flawed data: impossible statistics, incorrect calculations or duplicated numbers or figures, for instance. And in 26% of the papers had problems that were so widespread that the trial was impossible to trust, he judged — either because the authors were incompetent, or because they had faked the data.
Firstly, this is only from one journal, Anesthesiology. Second, the phrase "at least" indicates that while 44% had some amount of (presumably) flawed data, only 26% of the studies were bad enough to be judged fake or severely flawed by this one (admittedly esteemed) researcher in the field of anesthesiology. It's important to be skeptical and do your homework when you hear sweeping and/or shocking results. It's also important to read carefully, especially with science journalism because it is written for clicks and broad audiences, not to reduce ambiguity and adhere to strict standards of accuracy.
Aurornis|2 years ago
Correct, but this doesn’t constitute “fake data”. It could be that amyloid-β is a marker rather than a causative factor. Or it could be that amyloid-β related damage is downstream, and remove amyloid-β after the damage has been done won’t remove the other damage.
It’s too quick to wave away an entire field because a single theory didn’t pan out. Most medical research proceeds with a lot of dead ends before it is figured out.
xitrium|2 years ago